EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc.

Overview
Date Founded

2008

Headquarters

699 Boylston Street,8th floor,Boston, MA 02116

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Biotechnology

Company Description

EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on building a biosimilar business. It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference product. The company was founded on November 26, 2008 and is headquartered in Boston, MA.

Executives & Employees

Director of Finance

Paths to EPIRUS Biopharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
EPIRUS Biopharmaceuticals, Inc.
Recent Transactions
Details Hidden

Polpharma SA, Genefar BV purchase EPIRUS Biopharmaceuticals (Netherlands) BV from EPIRUS Biopharmaceuticals, Inc.

Details Hidden

Sun Pharmaceutical Industries Ltd., Taro Pharmaceuticals, Inc. purchase Zalicus Pharmaceuticals Ltd. from EPIRUS Biopharmaceuticals, Inc.

Details Hidden

EPIRUS Biopharmaceuticals, Inc. purchases Polpharma Biologics Utrecht BV

Transaction Advisors
Legal Advisor

Advised onPolpharma SA, Genefar BV purchase EPIRUS Biopharmaceuticals (Netherlands) BV from EPIRUS Biopharmaceuticals, Inc.

Legal Advisor

Advised onEPIRUS Biopharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onEPIRUS Biopharmaceuticals, Inc. issued USD Common Stock

Attorney

Advised onEPIRUS Biopharmaceuticals, Inc. purchases Polpharma Biologics Utrecht BV

Legal Advisor

Advised onEPIRUS Biopharmaceuticals, Inc. purchases Polpharma Biologics Utrecht BV

Legal Advisor

Advised onEPIRUS Biopharmaceuticals, Inc. purchases Polpharma Biologics Utrecht BV

Clients

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Genefar BV provides investment services. The company is headquartered in Amsterdam, the Netherlands.

Key Stats and Financials As of
Market Capitalization
$78.6K
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotech has access to the broader resources of TPG.

Details Hidden

Mousse Partners's clients include certain individuals and entities associated with the Chanel fashion house's business interests. Their strategy emphasizes alternative assets, especially private equity and hedge funds.

Details Hidden

5AM Ventures invests in next-generation life sciences companies located in the US. The firm targets companies operating in the fields of biopharmaceutical, drug delivery technologies and research instruments. They provides financing for early stage and corporate spin-out capital requirements with an investment size ranging from $20 to $30 million and also makes co-investments.

Suppliers
Reliance Life Sciences Pvt Ltd. Other Business & Consulting Services | Mumbai, India

Reliance Life Sciences Pvt Ltd. provides biotechnology clinical research services. Its services include pre clinical services, phase-I, biometrics, cardiac safety studies, medical writing, and pharmacovigilance. The company was founded by Dhirubhai H. Ambani in 2001 and is headquartered in Mumbai, India.

FUJIFILM Holdings Corp. Equipment & Office Supplies | Tokyo, Japan

FUJIFILM Holdings, Inc. engages in the development, production, sales and service of imaging, information, and document solutions. It operates through the following segments: Imaging Solutions, Information Solutions, and Document Solutions. The Imaging Solutions segment handles color films, digital cameras, optical devices, color paper, services and equipment for photofinishing, instant photo systems, etc. The Information Solutions segment deals with the equipment and materials for medical systems, life sciences products, pharmaceuticals, graphic arts, flat panel display materials, recording media and electronic materials, etc. The Document Solutions segment provides office copy machines/MFPs, printers, production systems and services, office services, paper and consumables, etc. The company was founded on January 20, 1934 and is headquartered in Tokyo, Japan.

Livzon Pharmaceutical Group, Inc. Pharmaceuticals | Zhuhai, China

Livzon Pharmaceutical Group, Inc. engages in the research and development, production, and distribution of pharmaceutical products. It offers drug preparation products, bulk medicines and intermediates, and diagnostic reagents and equipment. The company was founded on March 1, 1992 and is headquartered in Zhuhai, China.

Competitors
Celltrion, Inc. Biotechnology - Inchon, South Korea

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Biocon Ltd. Pharmaceuticals - Bangalore, India

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by EPIRUS Biopharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of EPIRUS Biopharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and EPIRUS Biopharmaceuticals, Inc..